Open Access

RESIDENT’S CORNER

New-onset psychosis following androgen deprivation therapy for prostate cancer

Daniel M. Bernad¹, Alan Dal Pra¹, Cintia Baule¹, Benicio N. Frey², Sergio Faria¹

1 DepartmentofOncology,DivisionofRadiationOncology,MontrealGeneralHospital,McGillUniversityHealthCentre,Montreal,Quebec,Canada
2 Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
Address correspondence to Dr. Daniel Bernad, Department of Oncology, Division of Radiation Oncology, Montreal General Hospital, 1650 Cedar Avenue, Montreal, QC H3G 1A4 Canada

Canadian Journal of Urology 2013, 20(4), 6868-6870.

Abstract

Androgen deprivation therapy (ADT) is commonly used in the treatment of prostate cancer and is associated with several side effects including psychiatric disorders. We present an unusual case of a 62-year-old man with high risk prostate cancer that developed de novo psychosis after starting luteinizing hormone-releasing hormone (LHRH) agonists and discuss possible mechanisms to explain such fndings. This case report highlights the importance of continuing assessment and monitoring of potential emotional and behavioral symptoms in prostate cancer patients treated with ADT.

---

Keywords

---